Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

3 One-Drug Biotech Wonders

on

  • 3,242 views

For Seattle Genetics, Medivation, and Regeneron, one drug is enough.

For Seattle Genetics, Medivation, and Regeneron, one drug is enough.

Statistics

Views

Total Views
3,242
Views on SlideShare
1,362
Embed Views
1,880

Actions

Likes
1
Downloads
7
Comments
0

9 Embeds 1,880

http://www.fool.com 1680
http://www.scoop.it 108
http://www.dailyfinance.com 81
http://www.barchart.com 4
http://translate.googleusercontent.com 3
http://cms.fool.com 1
http://mockup.www.fool.com 1
http://m.fool.com 1
http://cached.newslookup.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

3 One-Drug Biotech Wonders 3 One-Drug Biotech Wonders Presentation Transcript

  • 3 One-Drug Biotech Wonders
  • Sometimes One Is Enough • Biotechs often lose money for the first decade or more of their existence. • Going from no revenue to any revenue can drive stock price higher.
  • Seattle Genetics • Adcetris approved by FDA in 2011 to treat Hodgkin lymphoma and anaplastic large cell lymphoma after prior treatment failure. • Sold outside U.S. and Canada by partner Takeda Pharmaceutical • Receives revenue from partners that use Seattle Genetics’ technology to develop their drugs. Source: Seattle Genetics
  • Seattle Genetics
  • • Xtandi approved by FDA in 2012 to treat prostate cancer that has spread and has not responded to chemotherapy • Sold in U.S. with Astellas Pharma • Outside U.S., Astellas pays royalty from the low teens to the low twenties on aggregate net sales of Xtandi Source: Medivation
  • • Not technically a one-drug company, but other drugs added just $4 million in the third quarter. • Eylea, which treats macular degeneration, contributed $363 million. • Sold by Bayer HealthCare outside the U.S. where Regeneron gets half the profits. Source: Regeneron Pharmaceuticals
  • Check Out These Returns Company Date of approval Return since approval Seattle Genetics August 19, 2011 201% Medivation August 31, 2012 61% Regeneron November 18, 2011 465% Returns through January 29, 2014.
  • Biotechs Hoping to Be 1-Drug Wonders • Chelsea Therapeutics (NASDAQ: CHTP) – Developing Northera for neurogenic orthostatic hypotension (dangerously low blood pressure) – FDA decision expected by February 14, 2014 • MannKind (NASDAQ: MNKD) – Developing inhaled insulin Afrezza for diabetics – FDA decision expected by April 15, 2014 • Durata Therapeutics (NASDAQ:DRTX) – Developing Dalvance for bacterial skin infections – FDA decision expected by May 26, 2014
  • The Motley Fool’s Top Stock For 2014